International Journal of Clinical Research

Objective: To investigate and analyze the clinical data of acute retinal necrosis syndrome (ARNS) and evaluate the effect of clinical comprehensive treatment. Methods: 16 eyes were treated with intravitreal injection of ganciclovir, with an average dose of 2.78 ± 1.62. 12 eyes underwent vitrectomy+silicone oil tamponade+intravitreal injection (ganciclovir) and retinal photocoagulation during the operation. The patients were followed up for 4-12 months to observe the visual acuity, intraocular pressure, eye condition changes and retinal detachment. Results: No complications such as retinal detachment, optic atrophy, proliferativevitreoretinopathy occurred in all patients during the follow-up period, and no ARNs occurred in the contralateral eyes. The best corrected visual acuity (BCVA) of patients before and after treatment was improved to varying degrees. Conclusion: The etiology of ARN is mainly VZV or EBV. Combined systemic and local antiviral therapy combined with hormone therapy can effectively curb the progression of acute retinal necrosis syndrome, and maintain and improve the existing vision to a certain extent. On this basis, vitreoretinal surgery and silicone oil filling can significantly reduce the incidence of severe vision decline in ARNs patients, prevent complications, and effectively save the vision of patients.

Acute retinal necrosis; PCR; Ganciclovir